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Abstract 23 
 24 
The safety of measles vaccination is of great interest to public health practice 25 
and the general society. We have analyzed the adverse events following 26 
immunization (AEFI) of currently used measles-containing vaccines (including 27 
live attenuated measles vaccine, live attenuated measles and rubella combined 28 
vaccine, live attenuated measles and mumps combined vaccine, live 29 
attenuated Measles, Mumps and Rubella Combined Vaccine) in Anhui 30 
Province, China. From 2009 to 2014, 9.9 million doses of measles-containing 31 
vaccines were administrated and 1893 AEFIs were found (191.4 per million 32 
doses), of which, 33 serious adverse events (3.3 per million vaccine doses) 33 
were reported. 59.4% (1124 cases) were male cases, and 85.1% (1611 cases) 34 
occurred in persons aged < 1 year. 93.3% (1766 cases) occurred at the first 35 
dose of vaccination and 95.9% (1815 cases) were found within 3 days after 36 
vaccination. This study presents up-to-date data and suggests that the 37 
measles-containing vaccines used in Anhui Province of China are safe. 38 
 39 
 40 
 41 
 42 
 43 
 44 
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Introduction 45 
 46 
Measles is one of the most contagious diseases caused by the measles virus, 47 
a paramyxovirus of the genus Morbillivirus[1]. About twenty million measles 48 
cases occur every year, and in most countries of the world, measles is 49 
endemic[2]. Currently, no specific antiviral treatment is available for measles 50 
virus. The most effective way to control measles is through vaccination. Great 51 
progress has been made in global control of measles. The estimated number of 52 
death declined by 74% from 535,300 in 2000 to 139,300 in 2010[3]. However, 53 
measles remains one of the leading causes of death among young children 54 
worldwide and the current vaccination coverage of 85%, although reaching a 55 
historical height, is still below the desired World Health Organization (WHO) 56 
target of 95% (WHO: Measles Fact Sheet, March 2016), including some 57 
Western countries (Health & Social Care Information Centre: NHS 58 
Immunisation Statistics, England 2013-2014; 25th Sept 2014). Therefore it 59 
remains a long-term goal to communicate and engage to build public 60 
confidence and promote immunization. To this end, evaluation and monitoring 61 
of the vaccination safety is an important aspect of the global collaboration 62 
towards prevention and control of measles.  63 
China is the largest country in WHO’s Western Pacific Region. Although 64 
China has made great efforts in recent years to eliminate measles, the virus 65 
continues to spread and cause serious morbidity [4, 5], occurring in most 66 
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provinces of China [6-9]. The average annual reported incidence of measles in 67 
China has decreased from 572.0 per 100,000 from 1960-1969 to less than 10 68 
cases after the year 2000[10]. The average annual reported incidence of 69 
measles in Anhui Province has decreased from 13.2 per 100,000 from 70 
1986-1995 to 3.2 cases from 2009-2014[11]. 71 
Key to the effective implementation of MCV vaccination is the monitoring of 72 
the associated adverse events (AE) following measles-containing vaccine 73 
(MCV) (including measles vaccine, measles-mumps-rubella vaccine, 74 
measles-rubella vaccine, measles-mumps vaccine).  These common adverse 75 
events included fever, rash, injection site reaction, seizure, encephalomyelitis, 76 
thrombocytopenia, anaphylaxis, acute arthralgia (adults), acute arthritis (adults), 77 
parotid swelling and aseptic meningitis in pre-licensure studies and 78 
post-marketing studies [12-17]. To maintain effective vaccine safety monitoring 79 
of MCV, updated data should be provided in a timely manner, to ensure these 80 
vaccines are safe which will help in maintaining public trust in the vaccination 81 
program.  82 
MCVs have been widely used in Anhui. However, to date, the AEs have not 83 
been systematically analyzed. In this study, adverse events following 84 
immunization (AEFI) of MCVs (produced by Beijing and Shanghai Institutes) 85 
from January 1, 2009 through December 31, 2014 will be described and 86 
analyzed in detail, on the basis of reports from China Immunization Safety 87 
Surveillance System. 88 
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Materials and Methods 89 
 90 
China Immunization Safety Surveillance System 91 
 92 
Anhui started to use China Immunization Safety Surveillance System in 93 
2008(http://219.141.175.204/) [18]; this was a passive surveillance system. 94 
Vaccinations and adverse events reports were the important tasks of the 95 
Centers for Disease Control and Prevention (CDC) in China and were 96 
coordinated centrally. CDCs were distributed throughout the country at 97 
different levels – county, prefecture and province with increasing 98 
administrative powers. Any events associated with vaccination were reported 99 
to CDC, investigated and diagnosed by a group of appointed experts (see 100 
“Reporting and investigation of AEFI” for more details). Events categorizing 101 
and casualty assignment followed the national guidelines and were 102 
standardized with an inspection and quality control system. The data were 103 
reviewed monthly, quarterly and annually. The feedback, conclusions and 104 
recommendations were made and disseminated to all the organizations and 105 
industry involved in the vaccination program.  106 
In Anhui, the system covered all levels of CDC, including 16 cities and 105 107 
counties, and as of 2014, 19983 AEFIs had been reported from this system in 108 
Anhui. National guideline for the surveillance of AEFI[19] was issued by 109 
National Health and Family Planning Commission of the People’s Republic of 110 
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China (NHFPC) and China Food and Drug Administration (CFDA) in June 111 
2010, which described how to report AEFIs, what to report and when to report.  112 
In the National guideline for the surveillance of AEFI, based on World Health 113 
Organization (WHO) guidelines, an AEFI case was defined as the occurrence 114 
of event deemed to be caused by the vaccine. In our study, serious AEFIs, on 115 
the basis of WHO guidelines, referred to hospitalization, death, life-threatening 116 
illness, and permanent disability[12]. 117 
 118 
The scope and time limit of reporting 119 
 120 
On the basis of National guideline for the surveillance of AEFI, the scope and 121 
time limit of AEFIs reporting were divided into the following categories[19]①122 
within 24h: allergic shock, anaphylactic reaction without shock (urticaria, 123 
maculopapule, laryngeal edema, etc.), toxic shock syndrome, hysteria, 124 
syncope; ②within 5 days: fever (axillary temperature≥38.5℃), redness and 125 
swelling in the vaccination site (diameter > 2.5 cm), induration (diameter > 2.5 126 
cm), angioedema, the whole body suppurative infection (pyemia, toxicema, 127 
blood poisoning), local suppurative infection (phlegmon, lymphangitis and 128 
lymph node phlogistic, local abscess), etc.; ③within 15 days: measles scarlet 129 
fever-like rash, febrile convulsion, seizure, encephalitis and meningitis, 130 
anaphylactoid purpura, arthus reaction, polyneuritis, etc.; ④within 6 weeks: 131 
thrombocytopenic purpura, vaccine-related paralytic polio, Guillain-Barré 132 
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syndrome, etc.; ⑤within 3 months: sterile abscess in the vaccination site, 133 
brachial plexus neuritis, etc.; ⑥others: other serious adverse events related to 134 
the vaccination and any medical events believed to be connected with 135 
vaccination. However, if an event was beyond the above time limit, clinicians 136 
would report to China Immunization Safety Surveillance System if it was 137 
deemed to be caused by the vaccination, and the classification of the AEFI 138 
case was based on his/her diagnosis. 139 
In this study, classification of AEFIs was based on Definitions Criteria of the 140 
Brighton Collaboration. AEFIs included Fever(≥38℃, classified as Level 1 of 141 
diagnostic certainty), Rash(Level 1 of diagnostic certainty), A local reaction at 142 
or near injection site(Level 1 of diagnostic certainty), Anaphylaxis(One case in 143 
Level 3 of diagnostic certainty, the remaining cases in Level 1.), Seizure (Level 144 
1 of diagnostic certainty), Diarrhea(Level 1 of diagnostic certainty), 145 
Fatigue(Level 1 of diagnostic certainty), Encephalitis/Myelitis(Level 1 of 146 
diagnostic certainty), Thrombocytopenia(Level 1 of diagnostic certainty) 147 
reported in China Immunization Safety Surveillance System in Anhui from 2009 148 
to 2014[20-28]. Of these, serious adverse events referred to Anaphylaxis, 149 
Seizure, Encephalitis/Myelitis and Thrombocytopenia.  150 
 151 
Reporting and investigation of AEFI 152 
 153 
Medical Institutions, immunization units, CDCs, agencies for monitoring 154 
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adverse events of drugs, vaccine manufacturers and vaccine wholesale 155 
businesses were the responsible reporting units and reporters for AEFIs. When 156 
receiving a report of an AEFI case, the reporting unit was demanded to fill in a 157 
case-report table and present it to the county CDC. After verification, the county 158 
CDC should report it through China Immunization Safety Surveillance System. 159 
The county CDC staffs should investigate AEFIs and fill in detailed investigation 160 
forms for all AEFIs except those with clear diagnosis (e.g. fever, a local 161 
reaction). On the basis of the National guideline for the surveillance of AEFI [19], 162 
every county-level, prefecture-level, and province-level CDC must establish an 163 
expert database to investigate and diagnose AEFIs. When an adverse event 164 
occurred, health administrative department should select appropriate experts 165 
from the expert database according to the type of the AEFI to form an 166 
investigation and diagnosis group. Each group should be composed of 167 
epidemiologists, clinicians, pharmacists, and other relevant experts. Causality 168 
assessment standards consulted Causality Assessment of An Adverse Event 169 
Following Immunization published by WHO, it contained 4 steps: Step one. 170 
Eligibility: The first step was to decide if the AEFI met the minimum criteria for 171 
causality assessment as shown below. Step two. Checklist: The second step 172 
was a systematically reviewing of the available relevant evidence to determine 173 
possible causal sides of the AEFI 174 
(http://www.who.int/vaccine_safety/publications/aevi_manual.pdf). Step three. 175 
Algorithm: The third step followed the WHO algorithm to obtain a trend about 176 
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the causality with the information collected in the checklist. Step four. 177 
Classification: The final step classified the AEFI’s in terms of their association 178 
with the vaccination/vaccine according to the trend determined in the 179 
algorithm[12]. Usually, prefectural or provincial level experts were responsible 180 
for investigating deaths, life-threatening illnesses, and permanent disabilities; 181 
county-level experts were responsible for other AEFIs. Information from 182 
case-report form and detailed investigation form was reported to the Anhui 183 
CDC through China Immunization Safety Surveillance System. All serious 184 
AEFIs were investigated by experts of the county, prefectural, or provincial 185 
CDCs immediately after receipt of reports (Fig1).  186 
 187 
Locate Fig 1. A flow diagram for process for categorising events and 188 
assigning causality of AEFI in Anhui of China. 189 
 190 
Vaccine and data on vaccine administration 191 
 192 
The vaccines were derived by using measles virus Shanghai-191, mumps 193 
virus S79 attenuated strain, and rubella virus BRDⅡattenuated strain [29-32].  194 
In Anhui Province from 2009 to 2014, MR and MMR were used in routine 195 
immunization and MV and MM was used in supplementary immunization. 196 
Data of vaccine administration was reported by township vaccination units to 197 
the county CDCs every month; thereafter county CDCs reported the data to 198 
prefectural CDCs and prefectural CDCs then reported to Anhui Provincial CDC. 199 
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We use the data as denominator when calculating the incidence of AEFI. 200 
 201 
Data analysis 202 
 203 
We calculated the incidence of AEFI as per million doses, and examined the 204 
age and gender distribution of the AEFI. We analyzed dose of the vaccination, 205 
time intervals from vaccination to onset of symptoms, simultaneous vaccination, 206 
reported symptoms and case diagnosis. If more than one symptom was 207 
reported on one person, only the most serious diagnosis or the main symptom 208 
was recorded in China Immunization Safety Surveillance System. Serious 209 
AEFIs were described in detail for their importance. 210 
 211 
Results 212 
 213 
Adverse Events after MCV vaccination 214 
 215 
Between 2009 and 2014, a total of 9.9 million doses of the MCVs were used 216 
and 1893 AEFIs were reported in Anhui Province. No deaths were reported. 217 
The overall incidence rate of reported AEFIs was 191.4 cases per million 218 
doses with the annual incidence rate of AEFI ranging from 35.2 per million 219 
doses in 2009 to 280.4 per million doses in 2014, with 424.6 per million doses 220 
in 2013, which was the peak rate. There were 33 serious adverse events; the 221 
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overall rate was 3.3 per million vaccine doses, with the annual rate ranging 222 
from 5.7 per million doses in 2009 to 3.7 per million doses in 2014, with the 223 
peak rate of 5.8 per million doses in 2010. The incidence of AEFIs showed a 224 
rising trend; however the serious AEFIs represented a downward trend (Fig2). 225 
 226 
Locate Fig 2. The reported rates of adverse events after immunization 227 
with MCV in Anhui, China, 2009-2014. 228 
 229 
Types of adverse events 230 
 231 
Most of the AEFIs were fever, accounting for 55.8% (106.9 per million 232 
doses), rash (48.3 per million doses) and local reactions (29.3 per million 233 
doses). There were more male cases than females with a gender ratio of 234 
1.46:1.00. A total of 1124 male cases of vaccination had an adverse event 235 
(59.4% of the total cases). 85.1% of the adverse events were reported in 8-12 236 
months age group with a total of 1611 cases (Table 1). 237 
 238 
 239 
 240 
 241 
 242 
 243 
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Table 1 The adverse events (AEs) following measles containing vaccines (MCVs) in Anhui Province 2009-2014. 244 
AEFI No.of cases（per million） 
Gender Age groups Vaccines received 
Male Female 8∼12 months 2∼4years 5∼7years ≥8 years MR MMR MV MM 
No.of cases(Percentage) 
Fever            
37.0-<37.5°C 137(13.9) 70(51.1) 67(48.9) 121(88.3) 10(7.3) 2(1.5) 4(2.9) 85(62.0) 40(29.2) 12(8.8) 0(0.0) 
37.5-<38.5°°C 481(48.6) 306(63.6) 175(36.4) 432(89.8) 35(7.3) 9(1.9) 5(1.0) 318(66.1) 115(23.9) 47(9.8) 1(0.2) 
≥38.5°C 439(44.4) 247(56.3) 192(43.7) 369(84.1) 63(14.4) 3(0.7) 4(0.8) 234(53.3) 123(28.0) 80(18.2) 2(0.5) 
Local reaction(diameter)            
<2.5cm 153(15.5) 94(61.4) 59(38.6) 127(83.0) 20(13.1) 4(2.6) 2(1.3) 70(45.8) 67(43.7) 16(10.5) 0(0.0) 
2.5-<5.0cm 113(11.4) 63(55.7) 50(44.3) 97(85.8) 7(6.2) 2(1.8) 7(6.2) 35(31.0) 73(64.6) 4(3.5) 1(0.9) 
≥5.0cm 24(2.4) 19(79.2) 5(20.8) 16(66.6) 7(29.2) 0(0.0) 1(4.2) 5(20.8) 18(75.0) 1(4.2) 0(0.0) 
Rash 478(48.3) 289(60.5) 189(39.5) 413(86.4) 46(9.6) 6(1.3) 13(2.7) 317(66.3) 88(18.4) 72(15.1) 1(0.2) 
Anaphylaxis 14(1.4) 8(57.1) 6(42.9) 6(42.8) 0(0.0) 4(28.6) 4(28.6) 3(21.4) 3(21.4) 7(50.0) 1(7.2) 
Seizure 14(1.4) 6(42.9) 8(57.1) 8(57.2) 4(28.6) 1(7.1) 1(7.1) 4(28.6) 3(21.4) 7(50.0) 0(0.0) 
Diarrhea 12(1.2) 8(66.7) 4(33.3) 9(75.0) 1(8.3) 0(0.0) 2(16.7) 7(58.3) 2(16.7) 3(25.0) 0(0.0) 
Fatigue 4(0.4) 1(25.0) 3(75.0) 0(0.0) 0(0.0) 0(0.0) 4(100.0) 0(0.0) 2(50.0) 2(50.0) 0(0.0) 
Encephalitis/Myelitis 3(0.3) 1(33.3) 2(66.7) 2(66.7) 1(33.3) 0(0.0) 0(0.0) 0(0.0) 1(33.3) 2(66.7) 0(0.0) 
Thrombocytopenia 2(0.2) 2(100.0) 0(0.0) 1(50.0) 1(50.0) 0(0.0) 0(0.0) 1(50.0) 0(0.0) 1(50.0) 0(0.0) 
others 19(1.9) 10(52.6) 9(47.4) 10(52.6) 4(21.1) 2(10.5) 3(15.8) 5(26.3) 3(15.8) 11(57.9) 0(0.0) 
Total 1893(191.4) 1124(59.4) 769(40.6) 1611(85.1) 199(10.5) 33(1.8) 50(2.6) 1084(57.3) 538(28.4) 265(14.0) 6(0.3) 
Note: AEFI - adverse events following immunization  245 
MV - measles vaccine 246 
MMR - measles-mumps-rubella vaccine 247 
MR - measles-rubella vaccine 248 
MM - measles-mumps vaccine 249 
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As for the incidence of AEFIs following different types of vaccines, adverse 250 
events following MR were 273.3 per million doses, MMR were 137.1 per 251 
million doses, MV were 213.9 per million doses and MM were 7.9 per million 252 
doses from 2009 through 2014. 253 
 254 
Vaccination doses, reaction intervals and 255 
simultaneous vaccination. 256 
 257 
Majority of the AEFIs (1766, 93.3%) occurred following the first dose of 258 
vaccination. A much smaller number of AEFIs were reported following 259 
subsequent doses of MCVs: 63 (3.3%) AEFIs after the second dose, 38 (2.0%) 260 
AEFIs after the third dose, and 26 (1.4%) AEFIs followed the fourth dose. 261 
The AEFIs commonly occurred within 3 days after MCV vaccination (1815 262 
cases, 95.9%). Overall, 1177(62.2%) cases occurred on the day of 263 
vaccination, 638 (33.7%) cases happened between 1 and 3 days after 264 
vaccination, 47 (2.5%) cases took place in 4 to 7 days and 31 (1.6%) cases 265 
were in 8 to 36 days.  266 
MCVs were administered alone in 1091 (57.6%) out of the total 1893 AEFIs, 267 
in combination with other vaccine in 796 (42.1%) events and in combination 268 
with two other vaccines in 6 (0.3%) cases. In 802 cases of simultaneous 269 
administration, 581 (72.4%) cases followed the first dose of MCVs, and 221 270 
(27.6%) cases followed the second dose.  271 
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Serious AEFI 272 
 273 
The 33 serious AEFIs included Anaphylaxis, Seizure, Encephalitis/Myelitis 274 
and Thrombocytopenia. The male to female ratio was 1.06:1.00 in serious 275 
cases. A total of 17 male vaccine recipients had an adverse event (51.5% of 276 
the total cases). There were 17 cases of AEFIs aged from 8 to 12 months 277 
(51.5%), and 6 cases in 2 to 4 years old (18.2%); 5 (15.2%) cases of AEFIs 278 
were reported for both 5-7 year group and 8 year plus group. 279 
The top three vaccines associated with serious AEFIs were MV, MR and 280 
MMR. MV was associated with nearly half of the serious AEFIs with 17 cases 281 
(51.5%; rate 13.7 per million doses), followed by MR with 8 cases (24.2%; rate 282 
2.0 per million doses), and then by MMR with 7 cases (21.2%; rate 1.8 per 283 
million doses). There was only 1 case inoculated with MM (Table 2). 284 
 285 
Table 2 Serious AEFI in Anhui from 2009 through 2014. 286 
Serious AEFI Total MR MMR MV MM 
 No.of cases（per million） 
Anaphylaxis 14(1.4) 3(0.8) 3(0.8) 7(5.7) 1(1.3) 
Seizure 14(1.4) 4(1.0) 3(0.8) 7(5.7) 0(0.0) 
Encephalitis/Myelitis 3(0.3) 0(0.0) 1(0.3) 2(1.6) 0(0.0) 
Thrombocytopenia 2(0.2) 1(0.3) 0(0.0) 1(0.8) 0(0.0) 
Total 33(3.3) 8(2.0) 7(1.8) 17(13.7) 1(1.3) 
 287 
69.7% of the serious AEFIs were vaccinated with MCVs only, 90.9% of them 288 
occurred within 3 days, and also 90.9% followed the first dose. The seizure 289 
cases were short lived, generalised tonic-clonic in nature. 290 
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Discussion 291 
 292 
This report provides updated 6 year data on the adverse events following 293 
the use of MCVs in Anhui Province from 2009 to 2014 and suggests MCVs 294 
have a very good safety profile. The rate of reported adverse events after 295 
measles-containing vaccines from 2009 through 2014 in Anhui was 191.4 per 296 
million doses which was below the national rate 338.1 per million doses in 297 
China (calculated from 2010-2014 data, [33-38]), and there were no deaths. 298 
The specific rates of AEFIs for MR, MMR, MV and MM were also lower than 299 
the national rates [33-38]. The rate of serious AEFI cases was 3.3 per million 300 
vaccine doses, similar to 3.7 per million vaccine doses for the whole China 301 
[33-38]. This is an area that needs further study in future monitoring efforts. It 302 
is of interest to note that data during this period of MCV program did not show 303 
a pattern or cluster of adverse events that would be concerning. Further more, 304 
most of the AEFIs were minor reactions (e.g. injection site reactions, fever) 305 
which have been observed in the pre-licensure studies and other 306 
post-licensure studies [13, 15-17]. The demonstrated safety profile of the MCV 307 
vaccines from our study is re-assuring to public health providers and the 308 
general public. As the same sources of MCV vaccines have been used many 309 
other provinces in China, this data may also serve as a reference base for 310 
MCV program in other regions of the country. 311 
Both individual categories of common and serious AEFIs in our report also 312 
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had lower rates than the international background data. The top three AEFIs 313 
reported in Anhui Province from 2009 through 2014 were Fever (106.9 per 314 
million doses), Rash (48.3 per million doses), Local reaction (29.3 per million 315 
doses). These were much lower than the corresponding incidences mentioned 316 
in Immunization Safety Surveillance, which were 5-10% for Fever, 5% for 317 
Rash and 17-30% for Local reaction [11]. Similar trend was also seen in the 318 
serious AEFIs. The incidences of the serious AEFIs (Anaphylaxis, Seizure, 319 
Encephalitis/Myelitis and Thrombocytopenia) in our study were 1.4, 1.4, 0.3 320 
and 0.2 per million doses respectively. These were lower than the 321 
corresponding incidences in Immunization Safety Surveillance which were 322 
1-3.5 per million doses, 1 in 2000-3000 doses, 1 per million doses and 1 per 323 
30000 doses respectively [11].  324 
Of note, 59.4% of the AEFI cases were males. It could be a real biological 325 
phenomenon but could also be partly due to biased reporting. A majority of the 326 
AEFIs were reported in the children between 8-12 months old and also 327 
happened after the first dose of MCVs. In China, routine immunization 328 
schedules require that the first dose is inoculated when children grow up to 8 329 
month old, and the second dose is administered when they reach 18-24 330 
months. This data suggests that the first dose of MCVs may have higher risk of 331 
AEFIs than the second dose. However, the higher risk of AEFIs in the first 332 
dose may be partly due to the vaccination form, as the first dose of MCVs had 333 
a greater percentage (72.4%) of combined vaccines than the second dose 334 
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(27.6%). This was also seen in other studies [16, 33]. Irrespective of the 335 
precise reasons, the message here is that the surveillance of adverse events 336 
of MCVs should pay more attention to children under 1 year old and also to the 337 
first dose.  338 
Approximately 95.9% of AEFI cases happened within three days after the 339 
vaccination. This could be partly due to the fact that reactions that happened 340 
within a short time after the vaccination were more likely to attract attention 341 
from children's guardians and the doctor. On the other hand, the report 342 
deadline requirements (e.g. only local reaction and fever within five days after 343 
vaccination were demanded to be reported as AEFI) may also play a role. 344 
Similar observation was also made in other studies [16, 33-38].  345 
Improvement to the surveillance system following introduction of the 346 
National surveillance program in 2010 and the detailed Anhui provincial 347 
guidelines in 2013 would have only improved the detection rate of the AEFIs 348 
and the accuracy of these AEFIs, especially the serious events. However, 349 
these changes to the surveillance system did not seem to have a significant 350 
effect on the rates of overall AEFIs and the serious events. Specifically, a small 351 
rise in the rate of total AEFIs in 2010 was followed by a return of the rate in 352 
2011 which was similar to that in 2009; a dip in the rate of the serious cases in 353 
2013 was again followed by a recovery of the rate in 2014 to a level similar to 354 
that in 2012.  355 
Some limitations in this study must be acknowledged. China Immunization 356 
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Safety Surveillance System was passive so that it was possible that some 357 
AEFIs might not have been reported by this system; therefore there could be 358 
under-reporting. Furthermore, most of the AEFI cases were found within 3 359 
days following the vaccination, suggesting that there could be a bias when 360 
reporting AEFI cases, an inherent limitation of a passive reporting system. In 361 
addition, this study was a descriptive research and hence limited our ability to 362 
ascertain a causal relationship between the AEFI and the vaccine. 363 
Nevertheless, the overall rate and the incidence of specific types of AEFIs 364 
were well within the range reported elsewhere.  365 
To sum up, we did not observe a pattern or cluster of AEFIs that may be 366 
concerning. These results demonstrate that MCVs administrated in Anhui had 367 
a very good safety profile. 368 
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